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Abstract: The human ERBB2 proto-oncogene is widely considered a key gene involved in 
human breast cancer onset and progression. Among spontaneous tumors, mammary tumors 
are the most frequent cause of cancer death in cats and second most frequent in humans. In 
fact,  naturally  occurring  tumors  in  domestic  animals,  more  particularly  cat  mammary 
tumors, have been proposed as a good model for human breast cancer, but critical genetic 
and molecular information is still scarce. The aims of this study include the analysis of the 
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cat ERBB2 gene partial sequences (between exon 17 and 20) in order to characterize a 
normal  and  a  mammary  lesion  heterogeneous  populations.  Cat  genomic  DNA  was 
extracted  from  normal  frozen  samples  (n  =  16)  and  from  frozen  and  formalin-fixed 
paraffin-embedded mammary lesion samples (n = 41). We amplified and sequenced two 
cat ERBB2 DNA fragments comprising exons 17 to 20. It was possible to identify five 
sequence variants and six haplotypes in the total population. Two sequence variants and 
two  haplotypes  show  to  be  specific  for  cat  mammary  tumor  samples.  Bioinformatics 
analysis predicts that four of the sequence variants can produce alternative transcripts or 
activate  cryptic  splicing  sites.  Also,  a  possible  association  was  identified  between 
clinicopathological traits and the variant haplotypes. As far as we know, this is the first 
attempt to examine ERBB2 genetic variations in cat mammary genome and its possible 
association with the onset and progression of cat mammary tumors. The demonstration of a 
possible association between primary tumor size (one of the two most important prognostic 
factors)  and  the  number  of  masses  with  the  cat  ERBB2  variant  haplotypes  reveal  the 
importance of the analysis of this gene in veterinary medicine. 
Keywords:  v-erb-b2  erythroblastic  leukemia  viral  oncogene  homolog  2  (ERBB2);  Cat 
Mammary Tumors (CMT); Sequence Variants (SVs); Haplotypes; Splicing Sites (SS) 
 
1. Introduction 
Naturally occurring tumors in domestic animals that share a similar environment with humans and 
therefore might be exposed to similar risk factors have been recognized as an interesting opportunity 
for comparative oncology [1–3]. Cat mammary tumors have been proposed as a good model for human 
breast  cancer  (HBC)  [1,4–6],  mainly  because  show  similar  average  age  at  diagnosis,  risk  factors, 
histopathology, prognostic aspects (as tumor size and lymph node metastasis) and response to therapy. 
Recently,  Burray  and  collaborators  [7],  demonstrated  that  cat  pre-invasive  mammary  lesions  
(non-neoplastic and neoplastic), share the  full spectrum of morphologic features  with pre-invasive 
mammary lesions in women.  
Cat  mammary  tumors  are  the  third  most  common  neoplasm  in  domestic  cats  [8,9].  From  cat 
mammary  lesions,  approximately  80%  are  malignant  and  10–20%  are  benign  (neoplastic  and  
non-neoplastic lesions) [9]. It is important to be aware that benign lesions can subsequently undergo 
malignant transformation [9]. 
Clinical staging of feline tumors is based on the world health organization’s TNM classification for 
HBC  modified  to  tumors  in  domestic  animals  [10].  It  is  known  that  tumor  size  and  lymph  node 
metastasis are the two most important prognostic factors, which are also significantly correlated with 
each other [11]. Additional prognostic information can be gained from histopathology grading, mitotic 
cell count and by several molecular markers such as ERBB2 (v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2) [6,9,12]. 
The human ERBB2 proto-oncogene (also known as HER2, neu) comprises 27 coding exons and 
encodes a transmembrane tyrosine kinase receptor protein, which is a member of the epidermal growth Int. J. Mol. Sci. 2012, 13                       
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factor  receptor  family  [13,14].  The  HER  family  share  an  overall  structure  that  encompass  an 
intracellular  carboxy-terminal  tail  [15,16].  When  specific  sites  in  the  intracellular  domain  are 
phosphorylated,  several  signaling  pathways  that  contribute  to  cell  division,  migration,  adhesion, 
differentiation and apoptosis are activated [16]. 
ERBB2 gene amplification and protein overexpression were previously described for HBC [17,18] 
and  cat  mammary  tumors  [6,7,12,19].  Also,  ERBB2  RNA  overexpression  was  demonstrated  in  
15–25% of HBC cases, and in 55% of cat mammary tumors [6,20–22]. Additionally it is also known 
that ERBB2 gene amplification and protein overexpression confer poor prognosis in HBC [17,18] 
Genes  commonly  amplified  or  deleted  often  enclose  point  mutations  that  activate  or  inactivate 
them [23,24].  In  recent  years,  a  number  of  mutational  profiling  studies  have  attempted  to  further 
identify clinically relevant mutations in HBC. The most notable overall observation is the lack of 
evidence to support a significant association between ERBB2 single nucleotide polymorphisms and 
breast cancer initiation, despite the information supporting its role in breast cancer progression [25–27]. 
In fact, sequence variants can directly alter the sequence that will be translated into protein, but can 
also  affect  splicing  and,  as  a  consequence,  lead  to  the  appearance  of  truncated  proteins  
(as previously described for human erbB-2 protein) or to the lack of the correct gene product [28].  
Regarding cat mammary lesions, the detection of genomic sequence variants (SVs) was previously 
reported,  but  only  for  TP53  [29–31]  and  TWIST1  genes  [32].  Therefore,  there  is  no  information 
concerning the cat ERBB2 gene sequence variations in this type of lesion.  
In the present work, we attempted to analyze the cat  ERBB2  gene SVs in the  genomes of cat 
mammary lesions (which include benign and malignant lesions), determine frequent haplotypes and 
establish  putative  associations  between  SVs  and  mammary  tumor  clinicopathological  features. 
Considering this purpose, we partially isolated and sequenced the cat ERBB2 gene (comprising exons 
17 to 20) in normal samples and in mammary lesions. The normal cat genomic DNA was analyzed to 
detect de novo SVs and ascertain the wild type haplotype for comparison with respective genomic DNA 
sequences from mammary lesions. Moreover, we also performed in silico comparative studies with cat 
and human ERBB2 DNA, mRNA and protein sequences available in GenBank in order to establish the 
physical boundaries of cat ERBB2 gene exons. This analysis allowed the physical localization of SVs 
in the cat ERBB2 gene and also the prediction of splicing points. 
2. Results and Discussion 
2.1. Extraction of Genomic DNA from FFPET and Frozen Samples 
The mammary lesions were clinicopathologically characterized (n = 41; Supplementary Table 1), 
including  benign  non-neoplastic  and  neoplastic  lesions,  primary  malignant  lesions  and  metastatic 
lesions in regional lymph nodes and distant organs. Each mammary lesion was collected from a different 
cat with the exception of the metastatic samples. (cf. Supplementary Table 1 lesions 40 and 41).  
We analyzed 16  control samples (peripheral blood) of  which 10 were  obtained from cats  with 
mammary lesions and six disease-free cats (Supplementary Table 2). gDNA was obtained from the  
16 normal samples and all the 41 mammary lesion samples.  Int. J. Mol. Sci. 2012, 13                       
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The integrity of the gDNA obtained was confirmed by agarose gel electrophoresis. The gDNA 
isolated was analyzed in a NanoDrop spectrophotometer and showed satisfactory quality and quantity.  
2.2. Analysis of Cat ERBB2 Gene DNA Fragments from Exons 17 to 20: Structural Features 
Two DNA fragments from cat ERBB2 gene were amplified in order to analyze the DNA sequence 
between exons 17 to 20: ERBB2_17-18 (343 bp) and ERBB2_19-20 (548 bp) fragments. 
The PCR products obtained for the 16 normal samples were further sequenced. For each cat ERBB2 
gene sequence fragment (ERBB2_17-18 and ERBB2_19-20), an alignment was performed with DNA 
sequences obtained from normal samples. The consensus sequence achieved for each DNA fragment 
was  submitted  to  GenBank  and  used  as  reference:  HM132072  (cat-ERBB2_17-18;  Supplementary 
Figure 1) and HM196846 (cat-ERBB2_19-20; Supplementary Figure 2). 
The  comparative  analysis  of  cat  ERBB2_17-18  (GenBank:  HM132072)  and  cat  ERBB2_19-20 
(GenBank: HM196846) DNA sequences, with cat ERBB2 mRNA (GenBank: AY702651.1), human 
ERBB2 mRNA (GenBank: NM_001005862.1) and human ERBB2 DNA (GenBank: NM_004448.2) 
sequences, allowed us to define the exon boundaries of the sequence under analysis: exons 17 (cat 
ERBB2_17-18: 1–137 nt), 18 (cat ERBB2_17-18: 221–343 nt), 19 (cat ERBB2_19-20: 1–90 nt) and 20 
(cat ERBB2_19-20: 366–548 nt). In a broad analysis, cat ERBB2 exons 17, 18, 19 and 20 demonstrate 
respectively 89%, 91%, 93% and 93% similarity with the human counterpart. The cat ERBB2 intron 17 
shows  78%  of  similarity.  Human  ERBB2  intron  19  (715  bp)  was  revealed  to  be  larger  than  its 
counterpart in the cat, with only 275 bp. Nevertheless, a considerable identity was found between 
homologous sequences, corresponding to cat ERBB2_19-20: 91–220 nt (76%) and cat ERBB2_19-20: 
221–365 nt (64%) (cf. Supplementary Figure 2). 
A partial protein sequence was obtained translating the DNA sequence corresponding to ERBB2 
exons 17–20 (cat erbB-2_17-20; cf. Supplementary Figures 1 and 2). The cat-erbB-2_17-20 protein 
showed  100%  similarity  with  the  cat  protein  from  Ensembl  (Q49LT4_FELCA).  Furthermore,  
multi-alignment of the cat erbB-2_17-20 with human erbB-2 (NCBI UniProt P04626 partial protein 
sequence) showed 93.7% identity. 
In outline, the exon boundaries assigned in this work for cat ERBB2 DNA sequences are the same 
as the ones reported for AY685128.1 DNA sequence and confirmed in the GENSCAN web server. 
2.3. Sequence Variant Detection in Cat-ERBB2_17-18 DNA Sequences 
We were not able to detect any SV in the fragment 17–18 of cat ERBB2 gene, either in normal  
(n  =  16)  or  mammary  lesion  (n  =  41)  tissues.  Nevertheless,  the  alignment  between  our  reference 
sequence for cat-ERBB2_17-18 (HM132072) and cat mRNA sequence (AY702651.1) revealed one 
nucleotide variation at position 74, already identified in the alignments reported above (Supplementary 
Figure 1). However, this SV detected is a synonymous one. Int. J. Mol. Sci. 2012, 13                       
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2.4. Sequence Variants Detection in the Cat ERBB2_19-20 DNA Sequences 
We were able to analyze a total of 38 sequences for cat ERBB2 gene 19-20 fragments of which  
16 were normal and 22 mammary lesions. In fact, for this fragment, the other 19 mammary lesions 
could not be sequenced. 
The  alignment  between  cat-ERBB2_19-20  (GenBank:  HM196846)  and  cat  mRNA  sequences 
(GenBank: AY702651.1; exons 19-20) identified the presence of three synonymous SVs at sequences 
positions 9 nt, 425 nt and 437 nt (Supplementary Figure 2). 
In  normal  samples  (n  =  16),  it  was  possible  to  disclose  the  presence  of  three  genomic  SVs: 
HM196846:g.224A>G, g.360C>T and g.371G>A (Table 1). All three sequence variants were detected 
in heterozygous condition and the SV g.224A>G was also found in homozygous condition (Table 1). 
The percentage of allelic variants found in normal samples (Table 1) reinforces the assumption that  
the DNA reference sequence HM196846 could be considered the genomic wild type (Figure 1 and 
Supplementary Figure 2). 
Table  1.  Sequence  variants  detected  in  cat  ERBB2_19-20  fragment  in  normal  and 
mammary lesion samples: Hardy-Weinberg equilibrium test. Genomic SVs presence (+) or 
absence (0). (wt) wild type allele. (n) number of samples with the same genomic sequence. 
(%) Allelic frequency. Hardy-Weinberg equilibrium significant p-value < 0.05.  
A: cat-ERBB2_19-20 genomic sequence variants presence (+) or absence (0)  
Normal DNA sequences (n = 16): 
SVs  n = 7  n = 1  n = 3  n = 2  n = 1  n = 2 
g.[224A>G] + [wt]  0  0  +  0  +  + 
g.[224A>G] + [224A>G]  0  +  0  +  0  0 
g.[360C>T] + [wt]  0  0  0  0  +  0 
g.[371G>A] + [wt]  0  0  0  +  0  + 
Mammary Lesions DNA sequences (n = 22): 
SVs  n = 8  n = 5  n = 1  n = 1  n = 1  n = 4  n = 1  n = 1 
g.[153C>A] + [wt]  0  0  0  0  0  0  0  + 
g.[156T>G] + [wt]  0  0  +  0  0  0  0  0 
g.[224A>G] + [wt]  0  +  +  0  +  +    + 
g.[224A>G] + [224A>G]        +      +   
g.[360C>T] + [wt]  0  0  0  0  +  0  0  0 
g.[371G>A] + [wt]  0  0  0  +  0  +  0  0 
B: cat-ERBB2_19-20 genomic sequence variants frequency and Hardy-Weinberg equilibrium test 
Allele frequencies (%): 
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Lesion  Normal  Lesion  Normal  Lesion  Normal  Lesion  Normal  Lesion  Normal 
C  97.7%  100%  T  97.7%  100%  A  36.4%  62.5%  C  97.7%  96.9%  G  88.6%  87.5% 
A  2.3%  0%  G  2.3%  0%  G  63.6%  37.5%  T  2.3%  3.1%  A  11.3%  12.5% 
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0.12E−6    0.12E−6    0.7  0.5  0.12E−6  0.31E−4  0.75  0.37 Int. J. Mol. Sci. 2012, 13                       
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Figure 1. Cat ERBB2_19-20 wild type sequence and alternative splicing study. Schematic 
image regarding the wild type exonic boundaries and alternative splicing sites obtained by 
Human Splicing Finder (HSF). Red highlighted nucleotide numbers indicate wild type (wt) 
start  and  end  of  exons  19  and  20  (wt  exons  sequences  limited  by  red  boxes).  
Green/underlying nucleotides (nt) show the five sequence variants detected in the present 
work. HSF outcome is pointed out by Enhancers Motifs (EM) and Silencers Motifs (SM) 
splicing sites created (+) or abolished (−). For each SV, the Splicing Sites (SS) and Branch 
Point  motifs  (BPm)  created  or  broken  are  indicated.  BP  motifs  and  the  respective 
nucleotide are identifying in blue.  
 
We analyzed ERBB2_19-20 sequences, from 22 cat mammary lesion samples. The multi-alignment 
of these sequences with our reference sequence (HM196846) allowed the identification of five SVs 
(Table 1 and Figure 1). Hence, additional to the three SVs detected in the normal samples, two new 
genomic  SVs  (HM196846:  g.153C>A  and  g.156T>G)  were  identified  in  mammary  lesions.  It  is 
important to note that, regarding these two SVs, it was not possible to analyze the respective normal 
samples  once  most  of  the  material  was  obtained  from  the  FFPET  archive.  Therefore,  we  cannot 
conclude whether they were somatic mutations or inherited SVs. 
From the five genomic variants detected in the cat ERBB2_19-20 fragment, four were localized in 
the intronic region (HM196846: g.153C>A; g.156T>G; g.224A>G and g.360C>T; Figure 1) and one 
was located at the beginning of exon 20 (HM196846: g.371G>A; Figure 1). Since the allelic change 
(G to A), corresponds to the modification of codon GCG>GCA which translate to the same amino acid Int. J. Mol. Sci. 2012, 13                       
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(alanine), the HM196846: g.371G>A is a synonymous sequence variation (detected in normal and cat 
mammary lesions). 
The  cat  ERBB2_19-20  SVs  allelic  frequencies  showed  no  Hardy–Weinberg  equilibrium  
deviation (Table 1). 
Our data, and other from literature demonstrate that there is a great homology between the cat  
and human ERBB2 sequences. Taking into consideration this evidence, all sequence variants detected 
were  screened  for  potential  splicing  transcripts  using  Human  Splicing  Finder  (HSF;  Figure  1  and 
Supplementary Table 3). 
The ERBB2_19-20: g.360C>T SV analysis recognized the wild type splicing site (365/366 nt) with 
no indication of broken site motif. 
Three of the five variants detected showed bioinformatic predictions of aberrant splicing, creating 
de  novo  splice  sites  motifs  (Supplementary  Table  3).  The  ERBB2_19-20:  g.156T>G  SV  create  a 
potential new 3' splicing site at position 173/174 nt with a possible retention of a large part of intron  
19 sequence in exon 20 (Figure 1 and Supplementary Table 3). The variant sequence ERBB2_19-20: 
g.224A>G (position 134 nt of intron 19) creates two new potential splice sites: one at position 223/224 nt 
with a partial intronic retention generating an alternative end for exon 19, and the other putative new 
splice site was detected at position 227/228 nt, originating an alternative start for exon 20 with a partial 
intronic retention (Figure 1 and Supplementary Table 3). Finally, the cat-ERBB2_19-20: g.371G>A 
(position 6 nt of exon 20), showed a new splice site at position 370/371 nt that could create a 3' upstream 
exon 20 sequence deletion, originating a small exon 20 (from WT start 366 nt and variant end at 370 nt; 
Figure 1 and Supplementary Table 3).  
Considering the potential branch points, a significant variation between mutant and wild type motifs 
sequences were detected for two SVs. The g.224A>G SV, localized deeper in intron 19, create  a 
branch point site broken between 219–225 nt. The g.360C>T SV, localized at the end of intron 19, 
create a putative new site between 357–363 nt that can activate a cryptic splice site, probably in the 
exon 20 (Figure 1 and Supplementary Table 3). The Human Splicing Finder also enables the analysis 
of  auxiliary  splicing  sequences  as  enhancers  and  silencers.  In  this  case,  the  sequence  variants 
g.224A>G and g.360C>T, were predicted to create (+) or disrupt (−) a splicing enhancer/silencer by 
one or more bioinformatic splice prediction tools (Supplementary Table 3). Our results showed an 
intermediate  effect  on  the  splicing  efficiency  inducing  both  exon/intron  inclusion  and  skipping  
(Figure 1; Supplementary Table 3). 
2.5. Cat ERBB2_19-20 Haplotype Determination in Normal and Mammary Lesion Populations 
The five SVs identified in this work were used for the haplotype determination. We detected four 
haplotypes  in  normal  samples  and  six  in  cat  mammary  lesions  (Figure  2)  and  noticed  that  the 
haplotype  showing  the  higher  frequency  (h1;  Figure  2)  corresponds  to  our  reference  sequence 
HM196846.  The  samples  collected  from  the  same  animal  (normal  sample  versus  lesion  samples) 
exhibit  the  same  genetic  haplotypes.  The  most  important  feature  is  the  identification  of  specific 
haplotypes in the cat mammary lesions population, namely haplotypes 5 and 6. As previously reported 
for the sequence variants analysis, it was not possible to analyze the respective normal samples of the 
mammary lesions showing the haplotypes 5 and 6. Int. J. Mol. Sci. 2012, 13                       
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Figure 2. Cat normal and mammary lesion samples haplotypes determination concerning 
ERBB2_DNA 19-20 DNA sequence variants. Haplotype blocks frequency estimated by 
Linkage Disequilibrium (LD), for normal, lesion and total groups of samples. Triangular 
graphic  corresponds  to  the  total  samples  LD  analysis.  Sequence  variants  are  designate  
in  the  LD  graphic  and  in  haplotype  blocks  columns:  1-g.[153C>A];  2-g.[156T>G];  
3-g.[224A>G];  4-g.[360C>T]  and  5-g.[371G>A].  Haplotypes  sequences  are  indicated  
in blocks lines: 1 = CTACG; 2 = CTGCG; 3 = CTGCA; 4 = CTGTG; 5 = ATGCG;  
6 = CGGCG. 
 
All variant haplotypes were submitted to GenBank and  five accession numbers were provided: 
HM1968478  (haplotype  2);  HM196848  (haplotype  3);  HM196849  (haplotype  4);  HM196850 
(haplotype 5) and HM196851 (haplotype 6).  
2.6. Statistical Analysis of Cat Mammary Lesions, Clinicopathological Classifiers and Its Association 
with Haplotypes 
All  the  41  cat  mammary  lesions  analyzed  were  clinical  and  pathologically  characterized 
(Supplementary Table 1 and 2). The Pearsons correlation test between all classifier traits (SPSS software), 
demonstrated  the  occurrence  of  linear  correlations  between  several  clinicopathological  classifiers 
(Pearson significant p-values ≤ 0.05; Supplementary Table 4). 
We  observed  an  outstanding  number  of  correlations  that  can  be  interrelated  with  each  other.  
As  example:  lymph  node  invasion  versus  higher  vascular  infiltration  (p  <  0.01);  higher  vascular 
infiltration  versus  higher  necrosis  presence  (p  =  0.05);  higher  necrosis  presence  versus  higher 
nuclear/cellular pleomorphism (p < 0.01); higher nuclear/cellular pleomorphism versus lower number  
of  masses  (p  =  0.02);  lower  number  of  masses  versus  no  ovary-hysterectomy  (p  =  0.01);  no  
ovary-hysterectomy versus less malign lesions (p = 0.06); less malign lesions versus better clinical 
outcome (p < 0.01) (cf. Supplementary Tables 1 and 4). 
In  summary,  it  was  possible  to  highlight  important  biologically  correlations.  A  strong  positive 
correlation was observed between the mammary lesion pathological grade and the clinical outcome 
grade.  It means that at the same time as the lesion malignity increases, the clinical outcome also Int. J. Mol. Sci. 2012, 13                       
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worsens (Supplementary Tables 1 and 4). Also, worse clinical outcomes showed a correlation with 
histological characteristics of malignity, as, for example, a higher grade of vascular infiltration and 
nuclear/cellular pleomorphism. 
In  order  to  test  the  association  between  SVs  and  haplotypes  with  the  mammary  tumor 
clinicopathological features, we allocated the presence or absence of each sequence variant with each 
classifier trait and for each cat mammary lesion analyzed (cf. Supplementary Tables 1 and 2).  
The statistics analysis showed that the g.153T>G SV trend towards an association with the benign 
neoplastic lesions (χ
2 p-value < 0.05; Fisher exact test p-value >0.05 and negative Pearson’s correlation 
coefficient; Supplementary Table 5). 
Taking into account only the primary mammary lesions (benign and malignant), the association test 
between  haplotypes  frequency  with  primary  tumor  size  and  with  the  number  of  masses  (multiple  
or simple), point out to a putative association that was further scrutinized. For this evaluation we 
compared the genotypic haplotype frequency for the two classifier traits (Table 2) Considering the 
primary tumor size (Table 2: T1, T2 and T3), the occurrence frequency of haplotype 1 (wild type) is 
100% (3/3) for T1; 80% (8/10) for T2 and 50% (5/10) for the T3. The wild type haplotype (haplotype 1) 
frequency is 53% in neoplastic lesions with multiple number of masses and 83% in neoplastic lesions 
with few masses. 
Table 2. Cat mammary primary lesion genotype and their relationship with size and the 
number  of  masses.  Each  diploid  genotype  is  designated  by  its  constituent  haplotypes. 
Haplotypes: (h1) CTACG; (h2) CTGCG; (h3) CTGCA; (h4) CTGTG; (h5) ATGCG; (h6) 
CGGCG. Primary tumor size: (T1) < 2 cm diameter; (T2) 2–3 cm diameter; (T3) > 3 cm 
diameter; (T?) unknown size. (MaL) malignant lesions; (BeL) benign lesions; (*) Frozen 
samples; (#) FFPET samples. Primary tumor size classification is in agreement with the 1980 
World Health Organization’s TNM system, modified to tumors in domestic animals [10].  
Number of  
Masses 
Primary Tumor Size  Diploid 
T?  T1  T2  T3  Genotype 
Multiple  1 MaL 
*    2 MaL    h1/h1 
1 BeL 
*        h2/h2 
    1 MaL    h1/h6 
1 BeL 
#        h1/h5 
      1 MaL  h1/h4 
2 MaL 
*        h1/h3 
  3 MaL  1 MaL  1 BeL  h1/h2 
      1 MaL  h2/ h3 
Simple      1 MaL  1 MaL  h1/h1 
      1 MaL  h1/h2 
2.7. Discussion 
Because erbB-2 protein clearly has an important role in diagnostic and prognosis of breast cancer, 
the gene encoding it (ERBB2) is a natural target for investigation regarding polymorphisms that might 
indicate resistance or susceptibility for breast cancer development [33,14], reinforced by the idea that Int. J. Mol. Sci. 2012, 13                       
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polymorphisms might result in increased erbB-2 autophosporylation [25,34,35]. erbB-2 biochemical 
and genetic studies have revealed that erbB-2 intracellular kinase domain autophosporylation activate 
the  signaling  pathways  that  contribute  to  cell  division,  migration,  adhesion,  differentiation  and 
apoptosis [16,36–38]. 
In this study, we analyzed two cat ERBB2 fragments encompassing exon 17 to 20 that encode  
the following protein regions: outer justamembrane, transmembrane, inner justamembrane and part of 
the intracellular domain. In these, the intracellular tyrosine kinase region (257 amino-acids), exon 18 
encodes  for  the  3  first  amino-acids  and  exons  19  and  20  are  translated  into  the  subsequently  
95 amino-acid. 
Two  reference  sequences  were  accomplished  by  the  analysis  of  gDNA  sequences  obtained  
from  normal  samples:  GeneBank  references  HM132072  (cat  ERBB2_17-18)  and  HM196846  
(cat ERBB2_19-20). 
A  comparative  analysis  between  cat  and  human  ERBB2  DNA  sequences  from  exons  17  to  20 
(Supplementary  Figures  1  and  2)  was  also  performed.  These  demonstrated  a  high  percentage  of 
similarity. The exon boundaries assigned in the present work correspond to exons 17–20 from the 
human ERBB2-202 transcript variant that encodes the erbB-2 total size protein. The human and cat 
erbB-2 proteins also showed a great similarity (93.7%). 
Since genome and proteomic browsers are more advanced for humans than for the domestic cat, the 
DNA, mRNA and protein comparative in silico analysis allowed the acquisition of novel knowledge 
about the cat ERBB2 gene. Moreover, the great similarity with the human counterpart reinforces the 
idea that cat mammary tumors could be used as molecular models for HBC.  
It is now widely  accepted that cancer  results from the accumulation of mutations in the genes  
that directly control cell birth or cell death [39]. In fact, it has been argued that genetic instability is 
absolutely  required  for  the  generation  of  the  multiple  mutations  that  underlie  cancer  [40].  Single 
nucleotide polymorphisms represent the most frequent type of genomic sequence variation between 
individuals. Moreover, their widespread distribution in the genome and their low mutation rate enable 
the use of single nucleotide polymorphism as genetic markers of diseases phenotypic traits [41]. 
In  the  present  work,  we  analyzed  one  group  of  cat  normal  samples  (n  =  16)  and  another  of 
mammary lesions (n = 41). The absence of SVs in the cat ERBB2_17-18 fragment was demonstrated 
in all normal (n = 16) and cat mammary lesion (n = 41) gDNA sequences analyzed. 
In the cat ERBB2_19-20 DNA sequence, it was possible to detect three SVs in the normal and 
mammary lesion samples: two were localized in intron 19 and one in exon 20 (Figure 1). This last SV 
(HM196846: g.371G>A) located at the beginning of exon 20 was found to be a synonymous variant. 
In mammary lesion samples, it was possible to detected two additional SVs (HM196846:g.153C>A 
and g.156T>G) located in intron 19 (Table 1 and Supplementary Figure 2). 
It is known that splicing changes can lead to protein splice isoforms, namely the appearance of 
truncated proteins (already shown for the human erbB-2 protein) that have an active role in mammary 
tumors [42]. Since the ERBB2 gene seems to be conserved in the cat and human genomes, we in silico 
predict the effect of each sequence variant in the splicing, using the bioinformatic tool Human Splice 
Finder  (HSF) [28]. From the five SVs detected in the present work,  four were  found to be  good 
candidates for the occurrence of alternative splicing: HM196846: g. 156T>G; g.224A>G; g. 360C>T 
and g.371G>A (Figure 1 and Supplementary Table 3). The in silico data obtained was found to be very Int. J. Mol. Sci. 2012, 13                       
 
2793
promising, enhancing the value of the SVs detected. This, however must be experimentally confirmed 
future studies.  
The SVs detected were also analyzed for haplotype determination in order to genetically evaluate 
the  population  under  study.  The  cat  mammary  lesion  population  showed  more  genomic  sequence 
variations (64%; five SVs) than the normal one (56%; three SVs). The five SVs pairwise linkage 
disequilibrium analysis allowed the identification of six haplotypes in the total population, of which 
four haplotypes were observed in the normal population (Figure 2). The most frequent haplotype 1 
(Figure 2), that corresponds to cat-ERBB2_19-20 reference sequence (Genebank: HM196846), can  
be considered the major ancestral haplotype. In outline, the genetic analysis of the population in study  
(i.e., percentage of genomic variation and haplotype frequency) revealed that the cat mammary lesion 
population presents more genomic instability than the normal one.  
Our  data  unveil  several  linear  correlations  between  clinicopathological  traits.  A  strong  positive 
correlation was observed between the mammary lesion pathological grade and the clinical outcome 
grade. The cases with no ovary-hysterectomy presence showed a strong correlation with hormonal 
treatment presence, and also with higher primary lesions mass number, lower detection of necrosis and 
lower grade of nuclear/cellular pleomorphism. All of these clinicopathological correlations are known 
to be in concordance with occurrence of less malignant lesions. Also in agreement were the Pearson 
correlation  results,  which  also  detected  a  nearly-significant  relationship  between  cases  with  no  
ovary-hysterectomy presence and lower levels of malignity (hyperplasic and neoplastic benign lesions). 
In fact, fibroadenomatous hyperplasia is usually seen in young, sexually intact queens at the time of 
puberty  and  also  in  cats  receiving  prolonged  hormonal  therapy  (megestrol  acetate  or 
medroxyprogesterone acetate) used as contraceptives in females [43], and characterized by aggressive, 
rapid and abnormal proliferation of one or more mammary glands with progression to necrosis if left 
untreated [44,45]. In addition, fibroadenoma can evolve from one to all of the mammary glands [46]. 
Our data is therefore in agreement with the one reported in the literature. As far as we know, it is the 
first time that such extensive evaluations between clinicopathological traits have been undertaken in 
cat mammary lesions.  
In  order  to  recognize  a  potential  association  between  the  SVs  and  haplotypes,  some 
clinicopathologic staging traits of all the 41 cat mammary lesions analyzed in the present work were 
clinically  and  pathologically  characterized  (Supplementary  Table  1).  The  HM196846:153T>G  SV, 
only  detected  in  cat  mammary  lesions,  showed  a  moderate  association  with  the  benign  
neoplastic lesions. 
The multiple mammary lesion masses in cats are quite frequent [5]. They are often considered to be 
associated with hematogenous or lymphogenous involvement [3]. Besides, it is known that tumor size 
is one of the most important prognostic factors, the larger size being associated with an advanced stage 
of  pathology  [11,47,48].  Regarding  only  the  primary  lesion  samples,  our  results  demonstrated  a 
presumed association between the genotypes with haplotypes that are not wild type (haplotypes 2, 3, 4, 
5, 6) with multiple numbers of masses and higher primary tumor size (Table 2). Future studies are 
mandatory to confirm these putative associations between sequence variants with malignant tumors 
and between haplotypes with primary tumor size and with multiple numbers of masses.  Int. J. Mol. Sci. 2012, 13                       
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3. Experimental Section 
3.1. Biological Material 
In this study we used 22 formalin-fixed paraffin-embedded tissues (FFPET) and 19 frozen samples, 
corresponding to a total of 41 mammary lesions obtained from 40 different cats (with an exception for 
metastasis samples; Supplementary Table 1). 16 blood samples (normal samples), also analyzed, were 
recovered  during  mastectomy  treatment  (n  =  10)  or  other  routine  clinical  procedures  (n  =  6)  and 
immediately  frozen  to  preserve  the  DNA  (Supplementary  Table  2).  Accordingly,  ten  normal  and 
mammary lesions samples were collected from the same individuals. 
The frozen samples were kindly provided by “Trás-os-Montes Veterinary Hospital” and the “UPVet 
Small  Animal  Clinics  of  the  Institute  of  Biomedical  Sciences  Abel  Salazar,  University  of  Porto 
(ICBAS-UP)”. All FFPET samples belong to a collection of the Veterinary Pathology Laboratory of 
ICBAS-UP  and  to  the  Institute  of  Molecular  Pathology  and  Immunology  of  the  University  of  
Porto (IPATIMUP). 
All tissues were evaluated by pathological procedures. Cat mammary lesion biopsies correspond to a 
heterogeneous  group  of  samples  (non-neoplastic,  malignant  and  benign  neoplastic  lesions).  
The histological classification was undertaken in accordance with the Misdorp and collaborators (1999) 
classification for cat mammary tumors [49]. 
All experimental work was conducted according to ethical procedures approved (EC/12-04/POCI/ 
CVT/62940/2004; approval date from 02/12/2004 and beginning of the study in 01/07/2005) and was 
carried out in accordance with best practice and the laws of the countries involved. 
3.2. Genomic DNA Extraction 
The genomic DNA (gDNA) extraction from the FFPET was performed according to the protocol 
previously described by Santos and collaborators [50]. The isolation of gDNA from normal blood 
samples was performed with the QuickGene DNA Blood Kit S (Fujifilm Life Science) following the 
procedures described by the manufacturer. 
The gDNA extracted from all samples was analyzed by agarose gel electrophoresis (1% agarose gel, 
stained with ethidium bromide) in order to evaluate its integrity. Afterwards, the quantity and quality 
were measured in a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). 
3.3. PCR Amplification of Two Fragments from Cat ERBB2 Gene Comprising Exons 17 to 20 
This study focuses on cat ERBB2 DNA sequence from exons 17 to 20 that encodes for a part of the 
outer justamembrane region (exon 17), the transmembrane region (exon 17), the inner justamembrane 
region (exon 17 and 18) and the intracellular region including part of the kinase domain (exons 18, 19 
and 20). The four primers used were designed, based on two cat DNA sequences from the National 
Center  for  Biotechnology  Information  (NCBI)  genome  browser:  ERBB2  mRNA  (GenBank: 
AY702651.1) and ERBB2 gene partial sequence (GenBank: AY685128). The primer sequences were 
as  follows:  sense  5'-CTGTGACGTCCATCATTGC-3'(E17),  antisense  5'-CTTGTAGACAGTGCCA 
AAAGC-3'(E18), sense 5'-ATCCCTGATGGGGAAAATGT-3'(E19) and antisense 5'-GGCAATCTG Int. J. Mol. Sci. 2012, 13                       
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CACACACCA-3'(E20). Two DNA fragments were amplified and sequenced with two sets of primers, 
covering the exons 17–18 (primer set E17-E18; 343 bp sequence) and exons 19–20 (primer set E19-E20; 
548 bp sequence). 
The PCR amplifications made using gDNA from frozen and FFPET samples were performed in a 
termocycler (T-personal, Biometra) with standard reaction mixtures. The cycling conditions used were: 
initial  denaturation  of  5  min  at  94  °C,  followed  by  30  cycles  (denaturation  for  1  min  at  94  °C, 
annealing  for  45  s  at  50  °C  and  extension  for  1  min  at  72  °C)  and  one  final  extension  step  of  
10 min at 72 °C. The PCR products were analyzed by electrophoresis in 1.5% agarose gel, stained with 
ethidium bromide and visualized under ultraviolet light. 
3.4. Sequencing and Analysis of DNA Fragments 
The fragments obtained were further sequenced in both directions, applying the same set of primers 
used during PCR amplification. The sequences were analyzed in Vector NTI 10.3.0 software (Invitrogen 
Life Technologies) using the ContigExpress and Align modules. 
A search of the two final DNA reference sequences was performed using the bioinformatic resource 
BLAST (Basic Local Alignment Search Tool) of NCBI and Ensembl genome browsers. The predicted 
protein sequence was done with the NCBI bioinformatic resource BLASTP 2.2.21. The search for 
ERBB2 exon structure was performed in NCBI and Ensembl genome  browsers and in GeneCards 
database (version 3). 
Sequence  variants  identification  nomenclature  is  in  accordance  with  the  standard  nomenclature 
recommendations of the Human Genome Variation Society [51–53]. 
3.5. Bioinformatic Splice Prediction Based on the SVs Detected 
The database Human Splicing Finder (version 2.4) was used to predict the effect of each sequence 
variant on mRNA splicing sites (splicing donor/acceptor sites and branch point sequences) and to 
accurately predict disruption of splicing enhancer or silencer sites [28]. The consensus values (CVs) 
for  wild  type  and  variant  affected  splice  sites  and  splice  regulatory  sites  and  the  variations  of  the 
consensus values ( CV) obtained for the wild type and the variant motifs were analyzed. It is important 
to notice that the sequence variants that showed predictions with CVs higher than 70–80 and/or  CV 
reductions of at least 10%, are likely to affect splicing [28]. As a result, only SVs that demonstrated these 
values  were  considered  for  this  analysis.  With  respect  to  branch  point  (BP)  sequences,  the  HSF 
software only processes a 100 bp window and excludes branch point positions −12 nt to −1 nt from the 
exon beginning. 
3.6. Statistic Analysis in Normal and Mammary Lesion Cat Populations. Testing Through DNA 
Variant Sequences and Clinicopathological Features 
For  genomic  SVs  detected  by  experimental  analysis,  the  allele  frequency  deviations  from  
Hardy–Weinberg equilibrium (HWE) were evaluated by Chi-square test (significant p-value < 0.05; 
SNPAlyse software; DYNACOM).  Int. J. Mol. Sci. 2012, 13                       
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Pairwise linkage disequilibrium was estimated by a D' absolute value for all sequence variants. 
Based in linkage disequilibrium and Chi-square tests, haplotype frequencies were estimated for each 
group (normal and mammary lesions) and for the total population. This analysis was performed in the 
SNP and Variation Suite™ 7 (Golden Helix) and Haploview 4.2 software applications.  
The mammary lesions were clinicopathologically characterized with several tumor classifiers, such as 
histological grading, clinical staging, other pathological features and clinical outcome. For each classifier 
score linear type traits were established (higher score values were set for higher grade of malignity). 
Pearson correlation test allows the identification of significant linear correlations and also provide the 
orientation of that relation. Correlation analysis was completed between the different classifier traits in 
the SPSS version 17.0 (significant p values > 0.05).  
In  order  to  disclose  putative  associations  between  SVs  and  haplotypes  with  mammary  tumor 
clinicopathological  features,  we  allocated  the  presence  or  absence  of  each  sequence  variant  and 
haplotype  with  each  classifier  trait  and  for  each  cat  mammary  lesion  analyzed  (cf.  Supplementary  
Tables 1 and 2). 
A  Pearson  correlation  test  and  Crosstabs  two-way  and  multi-way  tables  were  performed.  The 
Crosstabs two-way tables provide the chi-square test (Pearson’s χ
2 Tests) and Fisher’s exact test as 
measures of association (SPSS version 17.0 software). The chi-square test was used to test associations 
of the allelic and haplotype frequency between groups or subgroups of samples (χ
2 Tests significant  
p-value < 0.05). The Fisher’s exact test correct the association test in the cases were at least  one 
expected  cell  count  is  less  than  5  (significant  p-value  <  0.05).  We  also  applied  Pearson  linear 
correlation test. 
4. Conclusions 
In human breast cancer, several studies considering the analysis of ERBB2 gene sequence variants 
were performed focusing on specific polymorphisms already recognized to be possibly associated with 
HBC pathology [27,54]. On the other hand, cat ERBB2 gene molecular data is very scarce, including 
limited information concerning specific SVs, namely in mammary lesions. The present study encloses 
the sequencing of large DNA fragments in order to identify de novo SVs that could be involved in cat 
mammary tumor onset  and progression. Our work focuses in two cat  ERBB2  genomic fragments, 
embracing exons 17 to 20. We detected sequence variants in the genomic fragment between exon 19 to 
20 that encode for 95 amino-acids of the kinase domain. Our results showed a higher rate of SVs in the 
genomic  fragments  that  encode  for  this  protein  region  responsible  for  its  accurate  activation.  In 
addition, the higher frequency of SVs in mammary lesions compared to the normal samples suggests 
that the occurrence of SVs in the ERBB2_19-20 fragment have a possible impact in the function of the 
erbB-2 protein. The detailed description of the experimental and in silico analysis performed intend to 
be helpful in future studies on this matter.  
The bioinformatics analysis with the Human Splicing Finder database predicted that four of the SVs 
can produce alternative transcripts that justify further investigation at the experimental level. 
Our data demonstrated the occurrence of linear correlations between several clinicopathological 
traits  and  also  showed  a  putative  association  between  the  five  non-wild  type  haplotypes  and 
clinicopathological traits, namely with primary tumor size and number of masses. Int. J. Mol. Sci. 2012, 13                       
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It is important to highlight that, as far as we know, the present study is the first report concerning 
cat  ERBB2  gene  analysis  in  normal  samples  and  mammary  lesions  with  special  emphasis  to  the 
detection of sequence variants, alternative splicing sites prediction, haplotypes disclosing and SVs 
association with clinicopathological traits. 
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